Rescriptor is a non-nucleoside reverse transcriptase inhibitor, or NNRTI,
which is one of three classes of antiretrovirals. The other two classes are
protease inhibitors and nucleoside reverse transcriptase inhibitors (NRTIs).
Each class interferes with HIV's ability to reproduce in a different way.
NNRTIs, such as Rescriptor, work at an early point in the virus'
replication cycle, interfering with an important chemical in the virus called
reverse transcriptase.
Rescriptor is a treatment, not a cure, for HIV-1 infection. Patients may
continue to have illnesses associated with HIV-1 disease. Treatment with
Rescriptor has not been shown to reduce the frequency of such illnesses,
and its effect on survival is not yet known. Therefore, patients should remain
under the care of a doctor while using Rescriptor. Rescriptor has
not been shown to reduce the spread of HIV-1.
The latest news about Rescriptor: "Study Finds Twice Daily Rescriptor® Enhances PI Effect, Decreases Viral Load Among HIV Patients Who Fail Indinavir Combination Therapy"
Go to the NNRTI Menu
Go to the Treatments for HIV/AIDS Menu
Go to the HIVpositive.us Main Menu
39